ShedRx alternatives: what else costs less or bills differently
As of November 20, 2026, ShedRx has no current month-to-month price that can be compared like for like ("starting as low as $239/mo" for tirzepatide and "GLP-1s from $159/mo"; no month-to-month or maintenance price printed), so the tables below list the programs that do print one.
Released · Last reviewed · how we verify
Tirzepatide: programs that print a comparable price
ShedRx cannot be placed on the like-for-like tirzepatide scale because its page shows no month-to-month figure that applies at the maintenance dose. These programs print a month-to-month, all-in tirzepatide price that applies at every dose or at the maintenance dose (read November 20, 2026).
| Program | Month to month, all-in | Basis | Year at that price | Lowest printed rate | Read |
|---|---|---|---|---|---|
| Collective | $85.58 | per month | $1,027 | $85.58 ($69 a month plus $199 a year) | 2026-11-20 |
| Mondae | $126 | per month | $1,512 | $114 (6-month plan, $684) | 2026-11-20 |
| NexLife | $129 | per month | $1,548 | $115 (12-month plan) | 2026-11-20 |
| Eden | $129 | per month | $1,548 | $129 (every month) | 2026-11-20 |
| Yucca Health | $139 | per month | $1,668 | $119 (12-month plan, $1,428 upfront) | 2026-11-20 |
| Fifty 410 | $199 | per 28-day cycle | $2,587 | $149.50 (8-week program at $299, not in all states) | 2026-11-20 |
| Emerge Weight Loss | $269 | per 28-day cycle | $3,497 | $224 (2.5 mg, per 4 weeks) | 2026-11-20 |
| OrderlyMeds | $299 | per month | $3,588 | $149 (2-month new-customer offer, $299) | 2026-11-20 |
Semaglutide: programs that print a comparable price
ShedRx cannot be placed on the like-for-like semaglutide scale because its page shows no month-to-month figure that applies at the maintenance dose. These programs print a month-to-month, all-in semaglutide price that applies at every dose or at the maintenance dose (read November 20, 2026).
| Program | Month to month, all-in | Basis | Year at that price | Lowest printed rate | Read |
|---|---|---|---|---|---|
| Collective | $75.58 | per month | $907 | $75.58 ($59 a month plus $199 a year) | 2026-11-20 |
| Mondae | $87 | per month | $1,044 | $69 (6-month plan, $414) | 2026-11-20 |
| Yucca Health | $89 | per month | $1,068 | $69 (12-month plan, $828 upfront) | 2026-11-20 |
| Eden | $99 | per month | $1,188 | $99 (every month) | 2026-11-20 |
| NexLife | $109 | per month | $1,308 | $95 (12-month plan) | 2026-11-20 |
| OrderlyMeds | $149 | per month | $1,788 | $74 (2-month new-customer offer, $149) | 2026-11-20 |
| Fifty 410 | $199 | per 28-day cycle | $2,587 | $199 (4-week program) | 2026-11-20 |
| Noom Med | $249 | per 28-day cycle | $3,237 | $249 (per 4 weeks, billed every 12 weeks) | 2026-11-20 |
Brand alternatives
FDA-approved brand medication bought direct costs more: Zepbound vials from $299 at 2.5 mg to $449 a month at 7.5–15 mg with refills inside 45 days (LillyDirect, ladder carried from October 15), and Wegovy pens $349 a month (NovoCare, read November 20, 2026). Insurance coverage of a brand drug usually beats any cash price; see the insurance page.
Limitations
Compounded tirzepatide and semaglutide are not FDA-approved and are not the same products as Zepbound or Wegovy. Switching programs means a new prescriber review; ask the new program how it handles your current dose.
Frequently asked
What is the main alternative to ShedRx?
As of November 20, 2026, ShedRx has no current month-to-month price that can be compared like for like ("starting as low as $239/mo" for tirzepatide and "GLP-1s from $159/mo"; no month-to-month or maintenance price printed), so the tables below list the programs that do print one.
How are alternatives chosen here?
By the same basis for every program: the compounded month-to-month, all-in price at the maintenance dose, read on the program’s own page on November 20, 2026, turned into a year’s cost (12 months, or 13 four-week cycles). Programs that print only a starting-dose or coupon price are listed separately, because their regular cost cannot be confirmed.
Sources
- FDA: Concerns with unapproved GLP-1 drugs used for weight loss (content current as of October 1, 2026; read November 20, 2026)
- Federal Register 91 FR 23431: proposed 503B bulks-list decision for semaglutide, tirzepatide and liraglutide (May 1, 2026; no final notice found as of November 20, 2026)
- Zepbound (tirzepatide) prescribing information on DailyMed (read November 20, 2026)
- Wegovy (semaglutide) prescribing information on DailyMed (read November 20, 2026)
- ShedRx pricing page (read November 20, 2026)